Centre places purchase order for one crore doses of Zydus Cadila's needle-free Covid vaccine

by PTI - Nov 7, 2021 08:39 PM +05:30 IST
Centre places purchase order for one crore doses of Zydus Cadila's needle-free Covid vaccineCovid-19 vaccine - representative image (Twitter)

New Delhi, Nov 7 (PTI) Zydus Cadila's three-dose Covid vaccine ZyCoV-D is set to be included in the national anti-coronavirus inoculation programme this month with the Centre placing a purchase order with the Ahmedabad-based firm for one crore doses, official sources said on Sunday.

The Union Health Ministry is learnt to have given the go ahead to initiate the preparatory work for the introduction of the indigenously developed world's first DNA-based Covid jab, which in all probability will be given to adults initially under the country's vaccination drive, sources in the know of developments said.

ZyCoV-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above.

'The Centre has already placed a purchase order with Zydus Cadila for supply of one crore doses of ZyCoV-D, each costing around Rs 358 excluding taxes, at the earliest. This price includes the cost of a disposable painless jet applicator which has to be used for administering each dose,' an official source said.

'The vaccine in all probability will be given to adults initially because of limited production capacity,' the source said.

Zydus Cadila is in a position to provide one crore doses of ZyCoV-D per month, company officials are learnt to have conveyed to the ministry.

For administering to adults, frontline workers and vaccinators will be provided a brief training for using the needle-free pharma jet application in actual field settings.

The three doses of ZyCoV-D are to be administered 28 days apart, with each dose comprising a shot in both arms.

ZyCoV-D received emergency use authorisation from the drug regulator on August 20.

Meanwhile, a comprehensive programme for paediatric immunisation including developing a priority list of comorbidities is being worked out by the NTAGI (National Technical Advisory Group on Immunisation) for the launch of ZyCoV-D and Covaxin.   As for the emergency use approval for Bharat Biotech's Covaxin in the 2 to 18 years age group by the Drugs Controller General of India, it is under expert opinion and evaluation, official sources said.

The Subject Expert Committee (SEC) on COVID-19 of the Central Drug Authority on October 12  had recommended granting emergency use authorisation to Covaxin for children and adolescents in the 2 to 18 years age group with certain conditions.

At present, every citizen who is 18 years or above is eligible for the vaccination drive.PTI PLB DV DV

Get Swarajya in your inbox everyday. Subscribe here.
Tags: 

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber
Comments ↓
Get Swarajya in your inbox everyday. Subscribe here.
Advertisement

Latest Articles

    Artboard 4Created with Sketch.